V8 Peptides — Engineered Performance
Research Library
CJC-1295 DAC Safety Profile: Preclinical Tolerability
CJC-1295 DACPreclinical

CJC-1295 DAC Safety Profile: Preclinical Tolerability

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What does the preclinical literature say about CJC-1295 with DAC safety and tolerability? In the open abstracts, rodent work reports normal body composition and growth in exposed GHRH-knockout mice and evidence of somatotroph proliferation, and the wider GH-axis literature describes tight feedback control by somatostatin and IGF-I. None of the cited abstracts is a formal toxicology study, and none reports immunogenicity or reproductive testing for this molecule. "Safety profile" is a regulatory term that research-grade material does not have. This article lists what was measured, what the controls were, which questions remain open and why the DAC form, as an albumin conjugate, raises specific questions. For laboratory research use only.

Searches for the "safety profile" of a peptide usually expect a list of adverse effects. For a laboratory reagent that does not exist in any regulatory sense, and for CJC-1295 with DAC the open literature is small. What can be reported honestly is what the early rodent papers measured, which endpoints they did not include, and which scientific questions a conjugate of this type raises. This article does that, and it is a research summary only; not for human or animal consumption. V8 supplies CJC-1295 (No DAC); the DAC form is not in the catalog.

What "tolerability" can mean in a rodent study

In an experiment on a GHRH analog the primary pharmacology is increased GH secretion and growth, so the observations that bear on tolerability are secondary: whether body composition is normal, whether the response is proportionate, whether unexpected tissue changes occur and whether animals behave normally. Observations of this kind are useful signals but they are not a toxicology assessment, which would include dose escalation, clinical pathology, histopathology of multiple organs and recovery groups under defined guidelines. The distinction matters because a statement like "well tolerated" in a paper abstract usually refers to the absence of visible problems in a small study, not to a formal evaluation.

QuestionWhat the cited abstracts reportWhat they do not report
Is growth and body composition normal in exposed knockout mice?Normal weight and length on the 24-hour interval; relative lean and subcutaneous fat mass normal in all exposed groups (Alba et al., 2006)Organ histopathology, clinical chemistry
Does the pituitary respond structurally?Increased total pituitary RNA and GH mRNA, consistent with somatotroph proliferation (Alba et al., 2006)Long-term pituitary morphology after exposure ends
Is the effect schedule dependent?Less effective at 48 and 72 hour intervals (Alba et al., 2006)Tolerability at different intervals
Does sustained GRF exposure have tissue consequences?Transgenic GRF expression increased GH and growth; females were unexpectedly fertile (Hammer et al., 1985)A formal safety evaluation; the model is genetic, not pharmacological
Is there an immune response to the conjugate?Not addressed in the cited abstractsAnti-drug antibody testing

The GH axis is a feedback system

Any assessment of a GHRH analog has to begin with the physiology it perturbs. The GHRH/somatostatin–GH–IGF-I system is described as a multivalent feedback network, with feedback and feedforward mechanisms acting within the intact somatotropic axis (Giustina and Veldhuis, 1998). Somatostatin attenuates the GH response to GRF, particularly during the trough phase of the ultradian rhythm; immunoneutralization of somatostatin in rats removed the difference between peak and trough responses (Tannenbaum and Ling, 1984). Those facts imply that the response to an analog is bounded by the animal’s own inhibitory tone, so the observed effect in intact animals is not simply proportional to exposure. The receptor itself is regulated: evidence from the ovine receptor suggests that the C-terminus has an inhibitory function and may be involved in down-regulation via internalization and phosphorylation (Gaylinn, 1999). Feedback and receptor regulation are the physiological reasons that sustained stimulation does not translate into unlimited response, and they are also the reasons that studies of persistent analogs need to report the timing and duration of measurements.

Pituitary effects as a design consideration

The knockout mouse study reported increased total pituitary RNA and GH mRNA and immunohistochemistry images consistent with somatotroph proliferation, which is the expected action of GHRH on its target cell and is part of the normal biology of the receptor (Alba and colleagues, 2006; Gaylinn, 1999). In a knockout background the response also includes restoration of a cell population that is hypoplastic when the hormone is absent, as the same group had shown in an earlier study of postnatal exposure with a GHRH analog (Alba and colleagues, 2005). The research implication is that pituitary histology belongs in any study that uses a long-persistence analog, with stereology or cell counts and appropriate control groups, so that proliferation can be distinguished from hypertrophy and from the normal restoration of a deficient gland.

Questions specific to an albumin conjugate

A peptide that forms a covalent complex with serum albumin raises questions that a free peptide does not. They are listed here as open research questions, not as findings.

  • Linkage stability. Maleimide-thiol adducts can undergo thiol exchange or stabilizing ring opening, and thiol exchange can release the conjugated drug (Fontaine and colleagues, 2015). Whether and how this occurs for a given conjugate in a given species is a measurable question.
  • Albumin modification. The conjugate chemically modifies albumin at its free thiol. Whether this alters albumin function or turnover in the test species is a question for the specific molecule.
  • Immunogenicity. Whether a modified albumin or a modified peptide elicits a response in a given species is not addressed in the abstracts cited here.
  • Exposure duration. Persistence beyond 72 hours in rats (Jetté and colleagues, 2005) means that a single administration produces exposure on a timescale that a short-acting analog does not, which changes the design of washout and recovery groups.

What good preclinical reporting would include

ItemWhy it is needed for tolerability questions
Pre-specified exclusion criteriaPrevents post hoc removal of animals that do poorly
Recovery or washout groupShows whether a change reverses after exposure ends
Multi-organ histology, not only the pituitaryDetects off-target tissue effects
Clinical chemistry panelDetects metabolic or organ function changes not visible by weight
Anti-drug antibody assayTests immunogenicity of the conjugate or its components
Timing relative to the GH rhythmThe response varies with phase
Test article identity and lotAn impure or mis-quantified stock can mimic a tolerability signal

Interpreting small studies

Most of the open literature on this molecule consists of small rodent studies, and small studies have predictable limits. A group size of a handful of animals cannot detect rare events, so the absence of a reported problem is weak evidence of its absence. Effects that appear only after longer exposure than the study lasted are invisible. Findings in a knockout background, where the endogenous hormone is missing, may not carry to animals with intact feedback, and the reverse is also true. The right summary of such a body of work is therefore narrow: in these animals, over this period, these endpoints were measured and looked as described. Anything broader is an extrapolation that the data do not support, and it should be labeled as such wherever it is repeated.

Investigators designing their own studies can use the same lens in reverse. Decide in advance which tolerability-relevant endpoints are part of the question, size the groups to detect effects of a stated magnitude, include a vehicle group handled identically, and report all animals. Doing so produces data that another laboratory can interpret and, if necessary, challenge.

It is also worth separating two kinds of absence. A finding that was looked for and not seen is informative; a finding that was never looked for is silent. Most tolerability-relevant questions about this conjugate fall in the second group, because the early papers were designed around growth and pituitary biology. Anyone building on this literature should therefore list the endpoints they need and check each against the methods sections of the primary papers, instead of inferring coverage from an abstract. Where a needed endpoint was not measured, the honest entry in a review table is "not reported", and the gap is a reason to design the measurement into a new study with appropriate approvals, not a reason to assume the answer.

Laboratory handling safety is a separate topic

The word "safety" has a second meaning at the bench. Handling a lyophilized peptide involves ordinary laboratory practice: avoid generating and inhaling powder, wear gloves and eye protection, open vials in a suitable enclosure and dispose of waste according to institutional policy. Storage and receiving practice are discussed in storing research peptides and what a normal peptide vial looks like. For identity and quality records see how to read a COA, the COA library and the purity testing article.

How to read claims you find elsewhere

Statements such as "well tolerated" or "no side effects" appear widely online. A responsible reading asks four things. Which species and how many animals? Over what period? Which endpoints were actually measured? And was the claim made in the paper or added by someone summarizing it? The cited abstracts here make no safety claim in the regulatory sense, and no inference should be drawn about use outside the laboratory. For the underlying chemistry and mechanism, see the CJC-1295 DAC research overview and the DAC versus no-DAC comparison. The full range of reagents is in the catalog.

For laboratory research use only.

Frequently asked questions

Does CJC-1295 DAC have a safety profile?

Research-grade material has no regulatory safety profile. The open literature has early rodent studies that report growth, body composition and pituitary endpoints, and no formal toxicology package in the cited abstracts.

What did the knockout mouse study report about body composition?

Relative lean mass and subcutaneous fat mass were normal in all exposed groups, and daily administration produced normal body weight and length.

Is pituitary proliferation a safety finding?

It is the expected action of GHRH on somatotrophs and part of the receptor biology. It is a reason to include pituitary histology and controls in any study.

Why does feedback matter?

Somatostatin and IGF-I feedback bound the response. In rats, neutralizing somatostatin removed the difference between peak and trough GH responses.

What questions are specific to an albumin conjugate?

Linkage stability, effects on albumin, immunogenicity and the consequence of exposure lasting days. The cited abstracts do not answer them.

Did the cited papers test immunogenicity?

Not in the abstracts cited, so it remains an open question for this conjugate.

What did the transgenic mouse study show?

Expression of human GRF increased mouse GH and growth rates, and females were unexpectedly fertile. It is a genetic model, not a drug study.

What would a proper tolerability design add?

Pre-specified exclusions, recovery groups, multi-organ histology, clinical chemistry, anti-drug antibody assays and timing records.

What does laboratory handling safety involve?

Ordinary precautions: avoid generating powder, wear gloves and eye protection, and dispose of waste per institutional policy.

Does V8 sell the DAC form?

No. V8 lists the no-DAC form, and this article is background for laboratory readers.

Related reading: CJC-1295 DAC vs No DAC: Which Form Fits the Assay?, CJC-1295 DAC History: From GHRH to Albumin Conjugate, CJC-1295 DAC Mechanism of Action and Half-Life.

References

  1. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
  2. Alba M, Schally AV, Salvatori R. Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog. Endocrinology. 2005;146(3):1506-1513. doi:10.1210/en.2004-1044
  3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  4. Hammer RE, Brinster RL, Rosenfeld MG, Evans RM, Mayo KE. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature. 1985;315(6018):413-416. doi:10.1038/315413a0
  5. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0353
  6. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-1957. doi:10.1210/endo-115-5-1952
  7. Gaylinn BD. Molecular and cell biology of the growth hormone-releasing hormone receptor. Growth Horm IGF Res. 1999;9(Suppl A):37-44. doi:10.1016/S1096-6374(99)80008-2
  8. Fontaine SD, Reid R, Robinson L, Ashley GW, Santi DV. Long-term stabilization of maleimide-thiol conjugates. Bioconjug Chem. 2015;26(1):145-152. doi:10.1021/bc5005262

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.